Boston, MA, United States
Boston, MA, United States

Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital . Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973. Wikipedia.


Time filter

Source Type

Patent
University of Virginia and Beth Israel Deaconess Medical Center | Date: 2016-08-03

Methods, systems, and computer-readable media for rapid 3D dynamic arterial spin labeling with a sparse model-based image reconstruction are disclosed. In one embodiment, a method includes acquiring magnetic resonance data associated with an area of interest of a subject. The magnetic resonance data includes associated with arterial spin labeling (ASL) of the area of interest. The method also includes performing image reconstruction on the acquired resonance data. The image reconstruction includes compressed sensing enforcing a model-based sparsity constraint, where the model-based sparsity constraint is based on an ASL signal prototype dictionary.


Patent
Beth Israel Deaconess Medical Center and The General Hospital Corporation | Date: 2016-11-15

Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of 1-antitrypsin.


Patent
Boston University and Beth Israel Deaconess Medical Center | Date: 2016-07-29

Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells.


Patent
Beth Israel Deaconess Medical Center | Date: 2016-09-27

Described herein are, inter alia, methods for diagnosing and treating arrhythmogenic cardiomyopathy (ACM) by detecting cardiac intercalated disk proteins, e.g., desmosomal proteins, mechanical and gap junction proteins, in buccal cells. Exemplary desmosomal and gap junction proteins that can be evaluated in the methods described herein include plakoglobin, plakophilin 1, desmoplakin, and Cx43. The methods can also include selecting and/or administering a treatment for ACM to the subject.


Patent
Beth Israel Deaconess Medical Center | Date: 2017-04-26

The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).


Patent
Brigham, Women's Hospital, Stanford University and Beth Israel Deaconess Medical Center | Date: 2017-01-04

Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.


Patent
Los Alamos National Security LLC, Beth Israel Deaconess Medical Center, Duke University and University of Alabama at Birmingham | Date: 2017-06-14

The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.


Patent
Childrens Medical Center Corporation and Beth Israel Deaconess Medical Center | Date: 2017-04-19

Filtration apparatuses, kits, and methods for rapid isolation of intact, viable mitochondria from tissues are described with mitochondria isolated by differential filtration through nylon mesh filters. Mitochondria can be isolated in less than 30 minutes using the filtration apparatuses, kits, and methods described.


Patent
Janssen Vaccines & Prevention B.V. and Beth Israel Deaconess Medical Center | Date: 2017-01-04

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.


Tsokos G.C.,Beth Israel Deaconess Medical Center
New England Journal of Medicine | Year: 2011

SLE is an autoimmune disease that predominantly affects women and typically has manifestations in multiple organs. Immune-system aberrations, as well as heritable, hormonal, and environmental factors, contribute to the expression of organ damage. Immune complexes, autoantibodies, autoreactive lymphocytes, dendritic cells, and local factors are all involved in clinical manifestations of SLE. Biologic therapies and small-molecule drugs that can correct the aberrant immune-cell function are being developed in the hope that they will be more effective and less toxic than current treatments. Copyright © 2011 Massachusetts Medical Society.

Loading Beth Israel Deaconess Medical Center collaborators
Loading Beth Israel Deaconess Medical Center collaborators